Clinical trials: Cemiplimab, active
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial studies the effect of cemiplimab in combination with low-dose paclitaxel and carboplatin in treating patients with squamous cell carcinoma of the head and neck that has come back (recurrent) or spread to other…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT04862650
- Testing
- Carboplatin, Cemiplimab, Paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Marcelo Bonomi
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
- Conditions
- SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
- Trial name
- NCT06444880
- Testing
- Ubamatamab, Cemiplimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called…
- Trial name
- NCT05352672
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 210 sites in United States, Argentina and 22 more
- Volunteers
- 1,546 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT06190951
- Testing
- cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab
- Where
- 104 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated…
- Trial name
- NCT06848088
- Testing
- Fianlimab+cemiplimab
- Where
- 11 sites in United States, Ireland
- Volunteers
- 48 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumors
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy.
- Trial name
- COMBINE-EGFR-1 (NCT04626635)
- Testing
- REGN7075, Cemiplimab, Platinum-based doublet chemotherapy
- Where
- 54 sites in United States, France and 5 more
- Volunteers
- 548 people
- Sponsor
- Regeneron Pharmaceuticals
Non-small Cell Lung Cancer Stage III
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with select N3 lymph node…
- Trial name
- NEO-SURG (NCT06449313)
- Testing
- Cemiplimab-Rwlc
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Georgetown University
Plasma Cell Myeloma
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study.
- Trial name
- NCT05669989
- Testing
- Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone
- Where
- 37 sites in United States, Australia and 15 more
- Volunteers
- 70 people
- Sponsor
- Sanofi
Melanoma
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naïve patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.
- Trial name
- NCT07511036
- Testing
- Cemiplimab, Lpilimumab, Fianlimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer (NSCLC)
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can…
- Trial name
- NCT05553834
- Testing
- Alirocumab and Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Nsclc, NSCLC Stage II
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
This research study is being done to find out if a drug called cemiplimab is safe in adult patients who have non-small cell lung cancer (NSCLC) that can be surgically removed (resectable Stage II, IIIA, or select IIIB NSCLC).
- Conditions
- Nsclc, NSCLC Stage II, NSCLC, Stage III, NSCLC Stage IIIB
- Trial name
- NCT07746388
- Testing
- Cemiplimab
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Cancer, Immune System Disorder
Montreal Immune-Related Adverse Events (MIRAE) Study
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in…
- Conditions
- Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
- Trial name
- MIRAE (NCT05139706)
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
This phase II trial tests how well a fixed dose combination (FDC) of cemiplimab and fianlimab before surgery (neoadjuvant) works in treating patients with stage IB-IIIB non-small cell lung cancer (NSCLC).
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- N-PLANC (NCT06918132)
- Testing
- Biospecimen Collection, Cemiplimab, Fianlimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma
- Trial name
- NCT06980038
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer.
- Conditions
- Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
- Trial name
- NCT07281417
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
This phase II trial tests how well cemiplimab and transarterial radioembolization (TARE) with yttrium-90 (Y90) SIR-Spheres, registered trademark, works in treating breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
- Trial name
- NCT06860815
- Testing
- Biopsy, Biospecimen Collection, Cemiplimab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with…
- Trial name
- NCT07281768
- Testing
- Oxaliplatin, Capecitabine, Cemiplimab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anaplastic Thyroid Cancer, Thyroid Cancer
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF…
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
- Trial name
- NEO-COMBATXL (NCT06902376)
- Testing
- Cemiplimab, XL092
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Basal Cell Carcinoma (BCC), First Line Treatment
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC)…
- Trial name
- CEMI-first (NCT06981325)
- Testing
- Cemiplimab
- Where
- 8 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non-small Cell Lung Cancer
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs".
- Trial name
- NCT05800015
- Testing
- fianlimab, cemiplimab, Pemetrexed
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 160 people
- Sponsor
- Regeneron Pharmaceuticals